USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PULMOKINE, INC.
City: SLINGERLANDS
State: NY
Zip+4: 12159-9385
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $887,597.00 3
SBIR Phase II $2,267,504.00 1

Award List:

A novel JAK inhibitor for the treatment of pulmonary arterial hypertension

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lawrence S. Zisman
Award Amount: $311,629.00
Abstract:
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined JAK1/JAK2 inhibitor or more selective JAK2 inhibitor for PAH that will be delivered by inhalation.… More

A PDGFR inhibitor for the treatment of pulmonary arterial hypertension

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lawrence S. Zisman
Award Amount: $351,008.00
Abstract:
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a devastating disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel highly selective platelet derived growth factor receptor (P DGFR) inhibitor for PAH that will be… More

An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lawrence S. Zisman – 518-573-8315
Award Amount: $2,267,504.00
Abstract:
DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with… More

IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lawrence Zisman – 518-573-8315
Award Amount: $224,960.00
Abstract:
Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC HEALTH RELEVANCE